| Heart failure--implications of the true size of the problem. | |
| | |
MedLine Citation:
|
PMID: 8774385 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We review current knowledge on the true size of the clinical condition known as 'heart failure' in terms of epidemiological information and in relation to the true clinical burden. Population studies, together with data from physician and general practitioner records, reveal a range of estimated heart-failure prevalence of 1-10%. Estimated incidence rates vary from approximately 0-1% per annum. Reasons for variation include age, sex and, possibly, methodology. In community studies, the five-year mortality is between 50-60% while, in patients requiring hospital admission, the annual mortality is 10-20% in those with mild-moderate symptoms, and as high as 40-60% in severe heart failure. While angiotensin-converting enzyme (ACE) inhibitor treatment does significantly improve mortality in all grades of symptomatic heart failure, the annual mortality in severe patients was still 36% in CONSENSUS I. It is obvious that the term 'heart failure' is insufficiently descriptive or specific to be an acceptable label for all patients who might benefit from treatment. As 'clinical' heart failure is often an advanced and irreversible state, studies of its antecedents are important in developing strategies aimed at retarding the progression from the asymptomatic to the symptomatic conditions. The true prevalence of the most common antecedent, left ventricular dysfunction, has received relatively little attention. |
| | |
Authors:
|
H J Dargie; J J McMurray; T A McDonagh |
Related Documents
:
|
2961425 - Responses of vasoactive hormones in congestive cardiac failure. 19491615 - Dual blockade versus single blockade of the renin-angiotensin system in the light of on... 12439425 - Acutely decompensated heart failure: opportunities to improve care and outcomes in the ... 8521885 - Refocus on diuretics in the treatment of heart failure. 8355485 - Prophylactic treatment of swine with bretylium for experimental cardiac catheterization. 3794095 - Alterations in left ventricular diastolic function with doxorubicin therapy. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of internal medicine Volume: 239 ISSN: 0954-6820 ISO Abbreviation: J. Intern. Med. Publication Date: 1996 Apr |
Date Detail:
|
Created Date: 1996-09-26 Completed Date: 1996-09-26 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8904841 Medline TA: J Intern Med Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 309-15 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Western Infirmary, Glasgow, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
therapeutic use Cost of Illness Female Health Care Costs Heart Failure / drug therapy, economics, epidemiology*, etiology Hospital Mortality Humans Incidence Male Population Surveillance Prevalence Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Advances in osteoporosis: better identification of risk factors can reduce morbidity and mortality.
Next Document: Assessment and diagnosis of heart failure.